News Breaks |
|
|
| February 19, 2013 |
| 05:55 EDT |  | BSX, BSX, BSX, BSX, RNST, RNST, RNST, RNST, HBHC, HBHC, HBHC, HBHC, IBKC, IBKC, IBKC, IBKC, HOMB, HOMB, HOMB, HOMB, SFNC, SFNC, SFNC, SFNC, OZRK, OZRK, OZRK, OZRK, PNFP, PNFP, PNFP, PNFP, UCBI, UCBI, UCBI, UCBI | Stephens to host a field trip
Bank Field Trip travels through Memphis, New Orleans, Little Rock, Nashville and Atlanta on February 19-22. |
|
|
News For BSX;RNST;HBHC;IBKC;HOMB;SFNC;OZRK;PNFP;UCBI From The Last 14 Days Check below for free stories on BSX;RNST;HBHC;IBKC;HOMB;SFNC;OZRK;PNFP;UCBI the last two weeks. |
|
|
| May 23, 2013 |
| 10:08 EDT |  | OZRK | On The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Blue Nile (NILE) downgraded to Sector Perform from Outperform at RBC Capital... Devon Energy (DVN) downgraded to Neutral from Overweight at JPMorgan... Fabrinet (FN) downgraded to Hold from Buy at Deutsche Bank... Flextronics (FLEX) downgraded to Hold from Buy at Deutsche Bank... Patterson-UTI Energy (PTEN) downgraded to Sell from Neutral at Goldman... Prosperity Bancshares (PB) downgraded to Market Perform at BMO Capital... Realty Income (O) downgraded to Sell from Neutral at Goldman... ReneSola (SOL) downgraded to Underperform from Neutral at Credit Suisse... Sanmina (SANM) downgraded to Sell from Hold at Deutsche Bank... Multiband (MBND) downgraded to Market Perform from Outperform at Northland Securities... DuPont (DD) downgraded to Sell from Hold at BGC Partners... Bank of the Ozarks (OZRK) downgraded to Neutral from Buy at Sterne Agee... Comerica (CMA) downgraded to Negative from Neutral at Susquehanna. |
|
| 08:14 EDT | | OZRK | Bank of the Ozarks downgraded to Neutral from Buy at Sterne Agee
 Subscribe for More Information |
|
| May 22, 2013 |
| 12:22 EDT |  | BSX | Boston Scientific says new data shows blood pressure reduction with Vessix
Boston Scientific reported interim data from the REDUCE-HTN clinical program, which demonstrated a significant and sustained reduction in the blood pressure of patients treated with the Vessix Renal Denervation System. Data on the first 41 subjects enrolled in the REDUCE-HTN clinical program were presented at the annual EuroPCR Scientific Program in Paris. Interim data highlights include: All patients underwent successful bilateral renal denervation treatment; At the primary endpoint of six months, patients experienced a significant 27.6 mmHg reduction in systolic blood pressure; No device-related adverse events or procedural renal artery complications were reported; Long term efficacy was demonstrated, with a sustained 28.4 mmHg reduction in systolic blood pressure in the subset of patients for whom 12-month data are available; Demonstrated success in treating various anatomies, including accessory renal arteries; Demonstrated short renal denervation procedural time. |
|
| 10:44 EDT | | BSX | Boston Scientific says Lotus system met primary performance endpoint in trial
Subscribe for More Information |
|
| 09:35 EDT | | BSX | Boston Scientific says trials show 'exceptional' safety, efficacy data on stents
Boston Scientific reported positive results from two trials evaluating new, innovative drug-eluting stent technologies, which are emerging treatment options for coronary heart disease. Data from the first human use NG PROMUS Clinical Trial evaluating the safety and effectiveness of the Promus PREMIER Everolimus-Eluting Platinum Chromium Coronary Stent System, and two-year follow-up data from the EVOLVE Trial comparing the safety and effectiveness of the SYNERGY Everolimus-Eluting Bioabsorbable Polymer-Coated Platinum Chromium Coronary Stent System to the PROMUS Element Stent System were presented at the annual EuroPCR Scientific Program in Paris. The primary investigator for one trial said, "The Promus PREMIER Stent demonstrated excellent safety and effectiveness with zero percent target lesion revascularization and stent thrombosis. In addition, the rate of technical success, the primary endpoint of the trial, was very high at 99.2%." |
|
| May 21, 2013 |
| 11:49 EDT | | BSX | Boston Scientific data show Bronchial Thermoplasty benefits for up to five years
Subscribe for More Information |
|
| 05:48 EDT | | BSX | OrbusNeich seizes Boston Scientific stents as part of patent infringement case
Subscribe for More Information |
|
| May 20, 2013 |
| 10:11 EDT |  | IBKC | On The Fly: Analyst Upgrade Summary
Subscribe for More Information |
|
| 09:41 EDT | | BSX | Supreme Court agrees to hear Medtronic-Boston Scientific patent case
Reported by SCOTUSblog live blog of court orders and opinions. |
|
| 07:06 EDT | | IBKC | IBERIABANK upgraded to Overweight from Equal Weight at Stephens
Stephens upgraded IBERIABANK due to valuation, improved expense management, and margin stabilization. Price target raised to $62 from $49. |
| |
| May 16, 2013 |
| 16:13 EDT | | BSX | Vascular Solutions files patent infringement complaint against Boston Scientific
Vascular Solutions (VASC) announced that it has filed a patent infringement complaint in the U.S. District Court for the District of Minnesota against Boston Scientific Corporation (BSX). The complaint alleges that Boston Scientific has infringed three patents owned by Vascular Solutions concerning rapid exchange guide extension technology by manufacturing and selling its Guidezilla guide extension catheter which received 510(k) clearance in March. Vascular Solutions is seeking an injunction against Boston Scientific prohibiting the manufacture and sale of its Guidezilla catheter as well as damages for lost profits and legal costs. |
|
| 07:51 EDT |  | BSX | Boston Scientific price target raised to $12 from $9 at JMP Securities
JMP Securities increased its price target on Boston Scientific as the firm believes after speaking with experts that S-ICD devices can be used in 50% of de novo implant cases, up from its previous estimate of 30%. The firm's FY13 and FY14 earnings estimates for the company are well above consensus levels and it reiterates an Outperform rating on the shares. |
|
| 07:28 EDT | | BSX | I/O Central to host a conference
Subscribe for More Information |
|
| May 14, 2013 |
| 15:33 EDT | | BSX | Boston Scientific has a conference call hosted by JPMorgan
JPMorgan Analyst Weinstein will host a conference call with CEO Mike Mahoney on May 17 at 11 am. |
|
| 08:32 EDT | | IBKC | IBERIABANK Chife Credit Officer Gregg Strader departs from company
Subscribe for More Information |
|
| May 13, 2013 |
| 07:20 EDT | | HBHC | Hancock Bank to host a conference
Subscribe for More Information |
|
| May 10, 2013 |
| 10:00 EDT | | BSX | On The Fly: Analyst Upgrade Summary
Subscribe for More Information |
|
| 09:03 EDT | | BSX | Boston Scientific receives CEO Mark approval for Rhythmia mapping system
Subscribe for More Information |
|
| 05:46 EDT | | BSX | Boston Scientific upgraded to Outperform from Market Perform at Wells Fargo
Subscribe for More Information |
|
|
|
|
|
